We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The role of data and safety monitoring boards in implementation trials: When are they justified?
- Authors
Fiscella, Kevin; Sanders, Mechelle; Holder, Tameir; Carroll, Jennifer K.; Luque, Amneris; Cassells, Andrea; Johnson, Brent A.; Williams, Stephen K.; Tobin, Jonathan N.
- Abstract
The National Institutes of Health requires data and safety monitoring boards (DSMBs) for all phase III clinical trials. The National Heart, Lung and Blood Institute requires DSMBs for all clinical trials involving more than one site and those involving cooperative agreements and contracts. These policies have resulted in the establishment of DSMBs for many implementation trials, with little consideration regarding the appropriateness of DSMBs and/or key adaptations needed by DSMBs to monitor data quality and participant safety. In this perspective, we review the unique features of implementation trials and reflect on key questions regarding the justification for DSMBs and their potential role and monitoring targets within implementation trials.
- Subjects
NATIONAL Institutes of Health (U.S.); CLINICAL trials monitoring; CLINICAL trials; DATA quality
- Publication
Journal of Clinical & Translational Science, 2020, Vol 4, Issue 3, p229
- ISSN
2059-8661
- Publication type
Article
- DOI
10.1017/cts.2020.19